A Comparison of Effect of Metformin in Combination with Glimepiride and Glibenclamide on Glycaemic Control in Patients with Type 2 Diabetes

Ujwala Gawali*1, Amruta Umate2

1Department of Pharmacology, Dr. V.M. Government Medical College Solapur, Maharashtra, India
2Department of Pharmacology, Dr. V.M. Government medical college Solapur, Maharashtra, India

Corresponding Author
Ujwala Gawali
Associate Professor, Dept of Pharmacology, Dr. V.M. Government Medical College, Solapur, MH, India
Email id-ujwalagawali1963@gmail.com

Abstract

Objective To compare the effects of combination therapy using metformin and glimepiride with metformin and glibenclamide combination on glycaemic control (HbA1c and plasma glucose) and lipid profiles (Total cholesterol (TC), Triglyceride (TG), low density lipoprotein cholesterol (LDL-C), High density lipoprotein cholesterol (HDL-C)) in type 2 diabetes mellitus patients who have inadequately control with metformin and glibenclamide monotherapy.

Research Design and Methods Patients with type 2 diabetes mellitus, inadequately controlled with metformin and glibenclamide monotherapy were enrolled in the study. Eligible patients were randomized into two groups to receive combination of metformin plus glimepiride (1000mg+2mg) and metformin plus glibenclamide (1000mg+10mg) for 12 weeks. Primary efficacy end points were changes in fasting blood sugar (FBS) and postprandial blood sugar (PPBS) from baseline to 4 weeks, 8 weeks and 12 weeks and changes in HbA1c from baseline to final assessment i.e. at 12 weeks. The secondary efficacy end point included changes in lipid profile from baseline to final assessment.

Results At the end of 12 weeks difference in reduction in fasting blood sugar( FBS) and Glycosylated haemoglobin (HbA1c) between the treatment groups was not statistically significant (p>0.05). But reduction in postprandial blood sugar (PPBS) was statistically more significant in glimepiride and metformin group (p<0.05). Changes in lipid profile parameter between the treatment groups not statistically significant. Both groups were well tolerated except hypoglycaemic events was more in glibenclamide and metformin combination group.

Conclusion Both groups have similar effect on FBS and HbA1c, whereas glimepiride and metformin combination therapy has superior effect on PPBS level reduction and significantly lesser incidence of hypoglycaemia. Increasing evidence support the importance of postprandial hyperglycaemia in glycaemic control with regard to the development of complications in the patients with diabetes. Data also indicates that postprandial hyperglycaemia may have greater effect on the development of cardiovascular complications compared with elevated fasting plasma glucose.

A more intensive approach by using metformin and glimepiride combination therapy in patients with type 2 diabetes mellitus inadequately controlled with metformin, glibenclamide monotherapy may improve the care of patients with diabetes and, ultimately, the outcome of these patients.

Key words: combination therapy, type 2 diabetes mellitus, Metformin, glimepiride, glibenclamide.
INTRODUCTION
Diabetes Mellitus is one of the most common non-communicable diseases with high incidence all over the world. Diabetes is undoubtedly one of the most challenging health problems in the 21st century [1].
DM is a spectrum of common metabolic disorders, arising from a variety of pathogenic mechanisms, all resulting in hyperglycaemia. Factors contributing to it are insufficient insulin secretion, reduced responsiveness to insulin, increased glucose production and abnormalities in carbohydrate, fat and protein metabolism [2].
DM is a chronic progressive illness that requires continuing medical care and proper patient self-management education to prevent acute complications and also reduce risk of long term complications which occur over a period of time [3].
Globally as of 2010, it is estimated that there were about 285 million people with type 2 DM, making it nearly 90% of all types of diabetic cases, which is equivalent to 6% of world’s population and the proportions are increasing at a fast pace [4].
Goal of therapy in DM are directed towards attaining normoglycaemia, reducing the onset and progression of complications, treating comorbidities and improving quality and quantity of life [5]. Evidence based guidelines for the comprehensive management of diabetes focus primarily on lifestyle changes, management of cardiovascular disease risk factors and management of blood glucose levels [6].
Conservative stepwise treatment approach initiated as monotherapy after failure of diet and exercise is changing to combination therapy as type 2 DM have evidence of 50% reduction in beta cell function and 50% of normal insulin sensitivity, single drug therapy addresses only one, so it is not optimal [3].
Combination therapy addresses both of them and aggressive treatment would improve patient outcomes while reducing overall health costs, it also makes therapeutic action to occur at lower doses and improves safety profile of drugs and early progression to combination therapy can maintain adequate control of blood glucose [7].
Clinical trials support the use of combination of antidiabetic agents with complementary mechanism of action such as sulphonylureas and metformin. It is a synergistic combination, sulphonylureas enhance insulin secretion whereas metformin acts to improve insulin sensitivity and suppress hepatic glucose output [8].
Metformin should be included in therapy for type 2 DM patients, if tolerated and not contraindicated, as it is the oral hypoglycaemic medication proven to reduce risk of total mortality according to United Kingdom prospective diabetes study (UKPDS) [5].
Combination treatment with metformin is more effective than sulphonylureas drugs alone in improving glycaemic control in type 2 diabetes, while also allowing a reduction of the dosage of each drug[9]. Glibenclamide and metformin is the most common anti diabetic combination used in clinical practice [10].
Glimepiride which is considered a third generation sulphonylurea agent has several beneficial pharmacological effects and side effects are less as compared to glibenclamide. Glimepiride may be associated with a reduced risk of myocardial damage compared with other SUS [11].
So combination therapy of metformin and glimepiride is supposed to be one of the best treatments available for type 2 DM. So the aim of the present study was to compare the efficacy and safety of metformin plus glimepiride combination with metformin plus glibenclamide combination on glycaemic control in patients with type 2 DM.

METHODS
Patients
All patients of type 2 DM presenting to diabetic clinic during study period were screened and those satisfying the inclusion and exclusion criteria were enrolled in the study.
The study was approved by Institutional ethics committee, written and Informed consent was
taken from all the patients where every aspect of study was explained in detail in the language they were familiar with.

Patients who had failed on monotherapy with metformin (2000 mg/day) or glibenclamide (20 mg/day) and diagnosed as type 2 DM cases as per American Diabetes Association diagnostic criteria’s were included in the study.\(^{[12]}\).

Patients of type 1 diabetes mellitus, patients with current insulin therapy or received insulin for more than six weeks in last 3 months, known hypersensitivity to biguanides and sulfonylurea, patients on chronic medication known to affect glucose metabolism, patients with renal disease, congestive cardiac failure, hepatic insufficiency were excluded. History of myocardial infarction, stroke, patients suffering from visceral neuropathy, cancer, systemic lupus, erythematous lupus, HIV, pregnant and lactating mothers, patients of alcohol and drug abuse were excluded.

Study design
This prospective, randomized, open labelled study was conducted in diabetic OPD of a tertiary care teaching government hospital during the period of December 2012 to July 2014. 90 patients fulfilling inclusion and exclusion criteria were randomized into two groups.

Baseline parameters such as Fasting Blood Sugar (FBS), Postprandial Blood Sugar (PPBS), Glycosylated haemoglobin (HbA1c), lipid profile parameters like Total–Cholesterol (TC), Low Density Lipoprotein–Cholesterol (LDL-C), High Density Lipoprotein–Cholesterol (HDL-C) and Triglycerides (TGs) were assessed at the time of enrolment.

Eligible patients were randomized to receive glimepiride plus metformin (1 mg+ 500 mg/day) or Glibenclamide plus Metformin (5 mg+ 500 mg/day) for first 2 weeks. This was done to reduce the side effects and improve the tolerance of the patients as per the guidelines. After that the dose of glimepiride was increased to 2 mg/day and metformin 1000 mg/day in group 1, and dose of glibenclamide was increased to 10 mg/day and metformin 1000 mg/day in group 2, for rest of duration of study.

Study assessments and end points
Study treatment was started on the day of randomization and continued for 12 weeks. FBS and PPBS were assessed at every visit, scheduled at 4 week intervals. Glycosylated haemoglobin (HbA1c) and Lipid profile [Total–C, LDL-C, HDL-C and TGs] were assessed at the time of enrolment and at final assessment. The primary efficacy end points were changes in mean levels of FBS and PPBS from baseline to 4 weeks, 8 weeks, and 12 weeks and changes in mean levels of HbA1c from baseline to final assessment.

The secondary efficacy end point included changes in mean levels of lipid profile from baseline to final assessment. Safety outcomes included adverse events, particularly hypoglycaemic symptoms and other adverse events.

Statistical analysis
Unpaired ‘t’ test for difference between two means were used to analyse continuous variables at baseline and ‘z’ test for difference between two proportions were used to analyse categorical characteristics at baseline. Efficacy end points in both treatment groups were analysed by paired ‘t’ test. Efficacy end points between two treatment groups were analysed by unpaired ‘t’ test. Safety outcomes in both treatment groups were analysed by ‘z’ test for difference between two proportions.

In analysis, ‘p’ value < 0.05 was considered statistically significant.

RESULTS
A total of 90 patients were enrolled in the study, 45 patients in glimepiride and other 45 patients in glibenclamide group. During the study period, 3 patients from glimepiride and 4 patients from Glibenclamide group were lost to follow up. Therefore, 42 patients in glimepiride and 41 patients in glibenclamide group were finally considered for analysis of data [Fig 1].

Baseline characteristics of both study groups which includes age, sex, BMI, weight, FBS,
PPBS, HbA1c and lipid profile parameters. Both the groups were comparable for all the characteristics in the study and there was no statistically significant difference between the two groups (p>0.05) (Table 1).
Fasting blood sugar was significantly reduced in glibenclamide at 4 weeks and 8 weeks as compared to glimepiride and the difference is statistically significant. But at the end of 12 weeks, there is no significant difference between the two groups (p>0.05) (Table 2).
Postprandial blood sugar was significantly reduced in glimepiride group at 4 weeks, 8 weeks and 12 weeks as compared to glibenclamide and the difference is statistically significant (p<0.05) (Table 3).
There was considerable decrease in both the groups in HbA1C % from baseline to 12 weeks but there was no statistically significant difference between both groups (p>0.05) (Table 4).
There was no statistically significant changes in lipid profile in both the groups (p>0.05) (Table 5). Adverse events were comparable in both the groups except in case of hypoglycaemia, the incidence of which was more in glibenclamide group and the difference was statistically significant (p<0.05) (Table 6).

**Table no. 1 Baseline characteristics of the study population**

<table>
<thead>
<tr>
<th>Variables</th>
<th>Glimepiride and metformin (n= 42)</th>
<th>Glibenclamide and metformin (n= 41)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs.)</td>
<td>52.78 ± 6.50</td>
<td>54.79 ± 6.32</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Weight (kgs.)</td>
<td>60.95 ± 7.30</td>
<td>59.90 ± 6.35</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>23.71 ± 3.46</td>
<td>24.77 ± 3.66</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>26</td>
<td>24</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Female</td>
<td>16</td>
<td>17</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>FBS* (mg/dl)</td>
<td>176.83 ± 17.70</td>
<td>171.8 ± 16.25</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>PPBS$^2$ (mg/dl)</td>
<td>250 ± 23.30</td>
<td>248.95 ± 28.2</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>HbA$_1$C (%)</td>
<td>9.37 ± 0.77</td>
<td>9.66 ± 0.96</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Lidt profile (mg/dl)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total cholesterol</td>
<td>184.69 ± 23.60</td>
<td>188.34 ± 23.54</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>LDL-C€</td>
<td>91.95 ± 5.4</td>
<td>91.90 ± 5.46</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>HDL-C£</td>
<td>39.59 ± 3.93</td>
<td>41.21 ± 4.94</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>TGs©</td>
<td>166 ± 12.88</td>
<td>168 ± 16.17</td>
<td>&gt;0.05</td>
</tr>
</tbody>
</table>

z test for gender, unpaired t test for other variables. Figures are expressed as mean ± SD.

# fasting blood sugar,$ postprandial blood sugar,€ low density lipoproteins,£ high density lipoproteins,© Triglycerides

**Table no. 2** Fasting blood sugar in both groups

<table>
<thead>
<tr>
<th>Duration of Study</th>
<th>glimepiride and metformin group</th>
<th>glibenclamide and metformin group</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>176.83± 17.69</td>
<td>171.76± 16.24</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>4 weeks</td>
<td>162.43± 18.54</td>
<td>151.61± 16*</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>8 weeks</td>
<td>149.6± 15.01</td>
<td>135.37± 12.96*</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>12 weeks</td>
<td>123.4± 17.36</td>
<td>121.07± 15.7</td>
<td>&gt;0.05</td>
</tr>
</tbody>
</table>

Unpaired t test, *- P<0.05 Figures are Mean ± Standard Deviation

**Table no. 3** postprandial blood sugar in both groups.

<table>
<thead>
<tr>
<th>Duration of Study</th>
<th>glimepiride and metformin group</th>
<th>glibenclamide and metformin group</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>250±23.30</td>
<td>248.95±28.19</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>4 weeks</td>
<td>212.86 ±20.69*</td>
<td>224.66±29.51</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>8 weeks</td>
<td>191.83 ±19.28*</td>
<td>202.37.93±28.77</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>12 weeks</td>
<td>169 45 ±16.56*</td>
<td>179.05.49±25.47</td>
<td>&lt;0.05</td>
</tr>
</tbody>
</table>

Unpaired t test, *- P<0.05 Figures are Mean ± Standard Deviation
Table no. 4  HbA1C between the groups from baseline to 12 weeks.

<table>
<thead>
<tr>
<th>Duration of Study</th>
<th>Glimepiride and metformin</th>
<th>Glibenclamide and metformin</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>9.37±0.77</td>
<td>9.66±0.95</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>12 weeks</td>
<td>8.56±0.75</td>
<td>8.82±0.91</td>
<td>&gt;0.05</td>
</tr>
</tbody>
</table>

Unpaired t test, Figures are Mean ± Standard Deviation

Table no. 5 Lipid Profile in both groups at 12 weeks.

<table>
<thead>
<tr>
<th></th>
<th>TOTAL-C</th>
<th>LDL-C</th>
<th>HDL-C</th>
<th>TGs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glimepiride and metformin</td>
<td>177.98±24.00</td>
<td>91.33±5.6</td>
<td>39.73±3.40</td>
<td>165.19±12.89</td>
</tr>
<tr>
<td>Glibenclamide and metformin</td>
<td>184.8±22.49</td>
<td>91.65±5.46</td>
<td>41.17±4.79</td>
<td>167.8±16.40</td>
</tr>
</tbody>
</table>

Unpaired t test, Figures are Mean ± Standard Deviation

Table no.6 Incidence of adverse events occurring among patients in both the groups over 12 weeks duration of study.

<table>
<thead>
<tr>
<th>Adverse Events</th>
<th>glimepiride and metformin</th>
<th>glibenclamide and metformin</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metallic taste</td>
<td>3</td>
<td>4</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Hypoglycaemia</td>
<td>2</td>
<td>9*</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Nausea</td>
<td>3</td>
<td>8</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Abdominal Pain</td>
<td>4</td>
<td>4</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Vomiting</td>
<td>2</td>
<td>3</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>1</td>
<td>2</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Dizziness</td>
<td>1</td>
<td>1</td>
<td>&gt;0.05</td>
</tr>
</tbody>
</table>

Z test, *- P<0.05, figures expressed as numbers

DISCUSSION

In the present prospective, randomized, open labelled study efficacy for glycaemic control and tolerability of glimepiride and metformin Combination group was compared with that of glibenclamide and metformin combination group. The rationale for combining a metformin, which is a biguanide with that of sulphonylureas, i.e. glibenclamide and glimepiride is that, they have different mechanism of actions. Metformin suppresses hepatic gluconeogenesis to reduce fasting glycaemia, and also increases peripheral glucose uptake, whereas sulfonylureas increase insulin release from the β-cells, and work as long as some amount of β-cell residual function is present. This therapy has been shown to provide synergistic effect in many studies and meta-analysis [14].

Glibenclamide and metformin is the most widely used combination therapy for type 2 DM. Glimepiride which is a third generation sulphonylurea agent can be given once daily even
side effects are less and may have potent anti-
oxidative, anti-inflammatory and angiogenic
properties and it may potentially repair tissue
damage by decreasing the levels of toxic advanced
glycosylation end products (AGE) and increasing
colony-stimulating factors, these are its beneficial
pharmacological effects over glibenclamide[15].
Glimepiride may be associated with a reduced
risk of myocardial damage compared with other
Several studies have demonstrated the
antihyperglycaemic effectiveness of this
combinations against the monotherapies but head
to head trials of glimepiride and metformin
combination versus glibenclamide and metformin
combination are few. Combination therapies
provide better glycaemic control than the
monotherapy with either metformin,
glibenclamide or glimepiride and these drugs are
most cost effective among the antihyperglycaemic
drugs [8,9,10].
In our study we used combination of glimepiride 2
mg and metformin 1000 mg once daily in one
group and other group received 10mg
glibenclamide and metformin 1000 mg
combination once daily for 12 weeks. Shimpi et
al [13], also used the same drug combination in
same doses as our study for 12 weeks.
In our study we found that, there was statistically
significant reduction in glycaemic control parameters like FBS, PPBS and HbA1c in both
the groups. Similar findings were reported by
Shimpi et al [13] and Ortiz et al [10].
In our study, we found no statistically significant
difference between the glimepiride and

glibenclamide with regards to FBS and HbA1c but
there was statistically significant reduction in
PPBS in glimepiride than the glibenclamide group
at 12 weeks.
But Shimpi et al [13] reported statistically
significant reductions in FBS, PPBS and HbA1c,
in glimepiride and metformin group as compared
to glibenclamide and metformin group.
Ortiz et al [10] over a trial of one year duration
reported between the glimepiride and metformin
combination and glibenclamide and metformin
combination groups, where the doses were titrated
every 3 months to ensure achievement of
glycaemic targets, there were no significant
differences between both groups in FBS and
PPBS levels throughout the study. At the end of
the study, HbA1C concentration was significantly
lower in the glimepiride and metformin
combination group (p value 0.025). A higher
proportion of patients from the glimepiride and
metformin combination group i.e. 44.6% as
compared to the glibenclamide and metformin
combination where only 26.8% reached the goal
of HbA1c of 7% at the end 12 months of treatment.
Sivakumar et al [16] reported over a 6 months trial,
glimepiride and metformin combination having
statistically significant reductions in PPBS and
HbA1c while glibenclamide and metformin
combination having statistically significant
reductions in FBS as compared to the other group.
Among the lipid profile parameters we did not
find significant changes in both the two groups
but in the glimepiride group the reductions were
only slightly numerically better than the
glibenclamide group.
Shimpi et al [13] in glimepiride and metformin
combination treatment found significant
reductions in TC, TG, and LDL-C while there was
increase in the HDL-C throughout the study while
in glibenclamide and metformin combination
group it caused reductions in TC, TG, but not the
extent of glimepiride and metformin combination
group and there were no changes in LDL-C and
HDL-C.
Ortiz et al [10] reported that lipid profile remained
without significant changes in both the groups
throughout the study where they measured
triglycerides and HDL-C.
Sivakumar et al [16] measured only total
cholesterol where they found significant
reductions in the glimepiride and metformin
combination group as compared to glibenclamide
and metformin combination group.
In our study the safety and tolerability elicited by
both combination groups were consistent with
previous studies. Glimepiride and glibenclamide-
group had an overall similar safety profile. The
most commonly noted adverse events were metallic taste, nausea, vomiting, diarrhoea, hypoglycaemia and abdominal pain. The adverse events were mild and none of the patients from either group discontinued the study drugs because of side effects, there was statistically significant incidence of mild to moderate hypoglycaemic episodes in glibenclamide as compared to glimepiride group.

In Study by Ortiz et al.[10] also a higher number of mild and moderate hypoglycaemic events was observed in the glibenclamide and metformin group (28.9%) in comparison to the glimepiride and metformin group (17.1%). Shimpi et al.[13] reported similar occurrence of hypoglycaemic episodes in both the groups.

CONCLUSIONS

Therefore, we conclude that both groups have similar effect on FBS and HbA1C, whereas glimepiride and metformin combination therapy has superior effect on PPBS level reduction and significantly lesser incidence of hypoglycaemia as compared to glibenclamide and metformin combination group. Increasing evidence support the importance of postprandial hyperglycaemia in glycaemic control with regard to the development of complications in the patients with diabetes. Data also indicates that postprandial hyperglycaemia may have greater effect on the development of cardiovascular complications compared with elevated fasting plasma glucose. A more intensive approach by using metformin and glimepiride combination therapy in patients with type 2 diabetes mellitus inadequately controlled with metformin, glibenclamide monotherapy may improve the care of patients with diabetes and, ultimately, the outcome of these patients. However, further long duration studies are required to elucidate long-term effects on glycaemic controls, lipid profile parameters as well as other metabolic parameters.

Acknowledgements: The authors would like to thanks Mangesh Raut for writing support.

REFERENCES


